chenodeoxycholic acid has been researched along with pioglitazone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Angioni, C; Geisslinger, G; Goebel, T; Heering, J; Kahnt, A; Kaiser, A; Merk, D; Paulke, A; Proschak, E; Rotter, M; Schmidt, J; Steinhilber, D; Weiser, T; Weizel, L; Wittmann, S; Wurglics, M | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
| Dufour, JF; Perazzo, H | 1 |
| Ando, O; Furihata, K; Kusuhara, H; Maeda, K; Nakayama, T; Sugiyama, Y; Takehara, I; Terashima, H; Watanabe, N; Yoshida, M; Yoshikado, T | 1 |
| Grønbæk, H; Heebøll, S; Vilstrup, H | 1 |
| Kumar, RB; Mathews, SE; Shukla, AP | 1 |
| Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Sanyal, AJ; Wilson, LA | 1 |
| Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN | 1 |
| Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M | 1 |
8 review(s) available for chenodeoxycholic acid and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2017 |
[Treatment of non-alcoholic fatty liver disease].
Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Risk Assessment; Vitamin E | 2018 |
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Vitamin E | 2018 |
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Transplantation; Mass Screening; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence; Propionates; Thiazolidinediones; Vitamin E | 2019 |
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E | 2020 |
7 other study(ies) available for chenodeoxycholic acid and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents; Drug Discovery; Enzyme Inhibitors; Epoxide Hydrolases; HeLa Cells; Hep G2 Cells; Humans; Liver; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2017 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques | 2010 |
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.
Topics: Adult; Atorvastatin; Bile Acids and Salts; Chenodeoxycholic Acid; Drug Interactions; Glucuronides; Glycochenodeoxycholic Acid; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters, Sodium-Dependent; Pioglitazone; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3; Symporters; Taurocholic Acid; Thiazolidinediones; Young Adult | 2017 |
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins | 2019 |